Menu
Recruiting NCT06271707

Stellate Ganglion Block

Phase IV Interventional Esophagectomy Pneumonectomy Lobectomy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: 0.5% bupivacaine, Saline.
Who it may be relevant to
Registry conditions: Esophagectomy, Pneumonectomy, Lobectomy. Basic parameters: 18 years — 85 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Left Sided Stellate Ganglion Blocks Impact on the Rate of Post-operative Atrial Fibrillation in Patients Undergoing Thoracic Surgery: A Pilot Study

Overview

The purpose of this study is to determine if the addition of an ultrasound guided left sided stellate ganglion block with bupivacaine in patients undergoing esophagectomy, pneumonectomy, or lobectomy will result in lower rates of postoperative atrial fibrillation as compared to standard of care.

Interventions

  • Drug 0.5% bupivacaine
    an ultrasound guided left stellate ganglion block with 5 mL of 0.5% bupivacaine
  • Other Saline
    an ultrasound guided left stellate ganglion block with 5 mL of saline

Primary outcome measures

  • an ultrasound guided left stellate ganglion block with 5 mL of saline. [Time frame: 168 hours after surgery]
  • Atrial fibrillation; Other arrhythmias; Adverse events. [Time frame: 168 hours after surgery]

Eligibility criteria

Inclusion criteria

  • Patients undergoing esophagectomy, pneumonectomy, or lobectomy aged 18-85.

Exclusion criteria

  • Patients who have an exclusion to regional anesthesia.
  • Patients who have exclusion to stellate blockade.
  • Patients who are pregnant assessed via self-report or pregnancy test if they have taken one

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Prevention

Study locations

United States · 1 center
  • University of Minnesota — Minneapolis

Identifiers

NCT: NCT06271707 · ANES-2024-32720

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗